Drug Profile


Alternative Names: BPX-501; BPX-501 and AP1903; BPX-501-AP1903; BPX-501-rimiducid; CaspaCIDe; CaspaCIDe™ DLI; Rimiducid activated BPX 501

Latest Information Update: 03 Jul 2017

Price : $50

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders; Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies
  • Phase I/II Immunodeficiency disorders; Infections
  • Phase I Haemoglobinopathies; Immunological disorders; Metabolic disorders

Most Recent Events

  • 23 Jun 2017 Efficacy and adverse events data from the phase II BP-004 trial in Haematological malignancies released by Bellicum
  • 23 Jun 2017 Updated efficacy and adverse events data from the phase I/II BP-004 trial in Haematological malignancies presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 23 Jun 2017 Bellicum plans a mid-stage clinical trial for Haematological malignancies (In adults, Second line therapy or greater) in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top